(VIANEWS) – PANORO ENERGY (PEN.OL), MONTEA (MONT.BR), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. PANORO ENERGY (PEN.OL)
1556.6% sales growth and 16.05% return on equity
Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.
Earnings Per Share
As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr3.14.
PE Ratio
PANORO ENERGY has a trailing twelve months price to earnings ratio of 8.31. Meaning, the purchaser of the share is investing kr8.31 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.05%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 180% and 2330.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 236.15M for the twelve trailing months.
Moving Average
PANORO ENERGY’s worth is below its 50-day moving average of kr26.99 and below its 200-day moving average of kr28.40.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PANORO ENERGY’s EBITDA is 64.9.
More news about PANORO ENERGY.
2. MONTEA (MONT.BR)
25.8% sales growth and 5.79% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 30/09/2023 the property portfolio represented a total surface of 1,921,172 m² spread across 94 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €3.82.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 21.23. Meaning, the purchaser of the share is investing €21.23 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.79%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 124.38M for the twelve trailing months.
Sales Growth
MONTEA’s sales growth is 5% for the present quarter and 25.8% for the next.
Yearly Top and Bottom Value
MONTEA’s stock is valued at €81.10 at 06:20 EST, under its 52-week high of €88.20 and way higher than its 52-week low of €61.90.
More news about MONTEA.
3. NAVAMEDIC (NAVA.OL)
20.7% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 33.05. Meaning, the purchaser of the share is investing kr33.05 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Moving Average
NAVAMEDIC’s value is above its 50-day moving average of kr37.45 and above its 200-day moving average of kr37.41.
Revenue Growth
Year-on-year quarterly revenue growth grew by 51.9%, now sitting on 502.65M for the twelve trailing months.
Sales Growth
NAVAMEDIC’s sales growth is 19% for the present quarter and 20.7% for the next.
More news about NAVAMEDIC.
4. SPAREBANKEN SØR (SOR.OL)
13.6% sales growth and 11.36% return on equity
Sparebanken Sør operates as an independent financial institution in Norway. It operates through two segments, Retail Market and Corporate Market. The company is involved in banking, securities trading, and real estate brokerage activities in Agder, Rogaland, Vestfold, and Telemark counties. It also provides leasing, mortgage, and property management services; and sells general insurance, occupational pension, and group life insurance products. The company was founded in 1824 and is headquartered in Kristiansand, Norway. Sparebanken Sør operates as a subsidiary of Sparebankstiftelsen Sparebanken Sør.
Earnings Per Share
As for profitability, SPAREBANKEN SØR has a trailing twelve months EPS of kr17.21.
PE Ratio
SPAREBANKEN SØR has a trailing twelve months price to earnings ratio of 8.31. Meaning, the purchaser of the share is investing kr8.31 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.36%.
Volume
Today’s last reported volume for SPAREBANKEN SØR is 4975 which is 98.77% below its average volume of 407087.
Moving Average
SPAREBANKEN SØR’s value is above its 50-day moving average of kr134.53 and way higher than its 200-day moving average of kr128.43.
More news about SPAREBANKEN SØR.
5. PERNOD RICARD (RI.PA)
7.9% sales growth and 13.85% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. Pernod Ricard SA was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €8.8.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 16.22. Meaning, the purchaser of the share is investing €16.22 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.85%.
Yearly Top and Bottom Value
PERNOD RICARD’s stock is valued at €142.70 at 06:20 EST, way below its 52-week high of €218.00 and higher than its 52-week low of €141.45.
More news about PERNOD RICARD.
6. ITERA (ITERA.OL)
7.1% sales growth and 86.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.76.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 16.91. Meaning, the purchaser of the share is investing kr16.91 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 86.07%.
More news about ITERA.
